SUMMARY Fibrinogen degradation, fibrin polymerisation, and the insertion of cross links into fibrin by fibrin stabilising factor lead to the appearance of new antigenic determinants. Antibodies against these antigenic sites may react specifically with the derivatives but not with the parent molecules. We have utilised a monoclonal antibody, which interacts with the cross linked fragment D dimer and related high molecular weight fibrin derivatives, to develop an enzyme immunoassay which measures cross linked fibrin derivatives in plasma and serum using D dimer as standard. Mean concentration in plasma from normal subjects was 75 ng/ml with an upper limit of about 144 ng/ml. Concentrations in patients with pulmonary embolism, deep venous thrombosis, arterial thromboembolism, and disseminated intravascular coagulation were raised in all cases. Confirmation of the specific increase of cross linked fibrin derivatives in patients with disseminated intravascular coagulation was obtained by parallel monitoring of their fibrin degradation products in serum using affinity chromatography and sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis. In many patients the plasma concentrations greatly exceeded the serum values of cross linked fibrin degradation products, suggesting that the procedure can measure fibrin derivatives in plasma which are absent from serum. 
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The insertion of y-y chain cross links into fibrin by fibrin stabilising factor (XIII.) generates new and probably unique antigenic deteminants, which can be detected in its plasminolytic cleavage products. ' 2 Polyclonal antisera containing such antibodies have been exploited in differentiating between fragments derived from cross linked fibrin such as D dimer' [3] [4] [5] or a family of high molecular weight fragments2 and those derived from fibrinogen and non-cross linked fibrin (fragments X, Y, D, and E). Theoretically, such antisera, after differential absorption to remove panspecific antibodies, could be applied clinically to detect and measure cross linked fibrin derivatives. In practice this has proved difficult because of the low titres of the antibodies which remain after adsorption.
We Measurement of cross linked fibrin derivatives in plasma procedures to measure fibrin degradation products, these monoclonal assays could allow a more precise separation between normal and abnormal samples; they would be capable of differentiating between fibrinolysis and fibrinogenolysis; they offer the possibility of monitoring the release of thrombus products during thrombolytic treatment; they have a potential role for screening patients at risk of developing thrombosis or for monitoring anticoagulant treatment; and there is the possibility that they will detect soluble fibrin derivatives which, while present in plasma, are incorporated into the clot and are therefore not measured in assays used on serum. Such an assay could find wide usefulness in evaluating hypercoagulable states.
We report a preliminary assessment of this procedure. While values are quantitated as the standard D dimer, it is now known that these antibodies also react with other cross linked fragments and we prefer to group these collectively as cross linked fibrin derivatives.
Material and methods
The groups studied were as follows: (a) 25 healthy leucopheresis donors; (b) seven patients with venographically proved deep venous thrombosis; (c) 14 patients with pulmonary embolism, showing typical features on ventilation and diagnostic perfusion lung scans; (d) four patients with arterial thromboembolism (surgically proved); and (e) 28 patients with laboratory evidence of consumption coagulopathy, having diagnoses characteristically associated with disseminated intravascular coagulation. All patients in this group fulfilled the criteria for disseminated intravascular coagulation described by Whaun and Oski.8 Except for several patients in group (e) no cases from our previous report were included.7 All patient groups were studied within 24 h of diagnosis. A further 50 healthy blood donors have been studied separately.
Citrated plasma was obtained by mixing blood (4.5 ml) with 0-1 M sodium citrate (0.5 ml). Plasma was obtained by centrifuging at 2000 g for 30 min. Aprotinin (500 kIU) (Trasylol, Bayer) was added after centrifugation to minimise deterioration on storage. Aliquots were frozen at -20°C for up to four weeks, thawed at 37°C, and assayed in batches for cross linked fibrin derivatives by enzyme immunoassay (see below). A coagulation profile (prothrombin time, activated partial thromboplastin time, thrombin time, and fibrinogen assay) was performed in group (e). The platelet count was determined using a Coulter particle counter (S plus IV). Serum was obtained by clotting blood (2 ml) with thrombin (20 IU) in the presence of soybean trypsin inhibitor (3670 NF units), using FDP tubes (Burroughs Wellcome). This serum was also used to assay soluble cross linked fibrin derivatives by the same method used with plasma.
Fibrinogen/fibrin degradation products were measured (1) by a latex procedure (Dade Latex Antifibrinogen); and (2) by sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis (PAGE)9 following affinity gel separation using antifibrinogen serum coupled to cyanogen-bromide activated Sepharose 4B according to the method of Lane,'" modified by increasing the incubation time to overnight at 4°C rather than 2 h at 37°C (group e). This resulted in almost complete recovery from serum.
MATERIAL

Purified proteins
The purification of fibrinogen, fragments XYDE, and the cross linked fragments D dimer, D dimer-E, and high molecular weight cross linked fibrin fragments has been described previously.7 Protein determination was performed by the method of Rylatt and Parish." The preparation and properties of the monoclonal antibodies used in this study have also been described.6
METHODS
Immunoassay of cross linked fibrin fragments Two monoclonal antibodies were selected for developing the enzyme immunoassay of cross linked fibrin derivatives. One (coded DD-3B6/22) was monospecific for an antigen expressed on D dimer and related complexes known to contain cross linked y-y chains-for example, D dimer-E and high molecular weight complexes. It performed efficiently as a capture antibody unlike the monoclonal antibody coded DD-1 C3/108 used in the previous study. The other (coded DD-4D2/182) was panspecific, binding fibrinogen and both fibrinogen and fibrin degradation products, except purified E and degraded fragment D (D )
These antibodies were utifised in a capture-tag situation using the monospecific antibody DD-3B6/22 as the capture antibody on a solid phase consisting of round bottomed 96 well polyvinyl microtitre plates (Dynatech). Fifty microlitres of monoclonal antibody DD-3B6/22 (10 ug/ml in 0-1 M carbonate coupling buffer pH 9-6) was bound to the plate for 1 h at room temperature. Each subsequent incubation step was carried out at room temperature followed by four washes using phosphate buffered saline (pH 7.4) containing 0-2% Tween 20 and 0-5 M NaCl (PBS/T/S). monospecific anti-with a serum assay,' although with a slightly lower )n-reactive.
range. All patient groups were clearly different from ross linked fibrin the control group, without overlapping. Mean values (Fig. 2) showed a (calculated arithmetically) were as follows: normal eported previously 75 ng/ml; pulmonary embolism 1251 ng/ml; deep venous thrombosis 1096 ng/ml; arterial thromboembolism 2817 ng/ml; disseminated intravascular coagulation 8259 ng/ml. The With few exceptions (studying 45 patients in groups b-e) serum values were appreciably lower than plasma values of fibrin derivatives (Fig. 5) The conditions of the assay described here permit the detection of concentrations of D dimer down to Whitaker, Elms, Masci, Bundensen, Rylatt, Webber, Bunce 1 ng/ml. With modifications, including altered molarity of the buffers, more nearly linear binding curves can be obtained, facilitating the assay of high concentrations without the need for high plasma dilutions.
Discussion
The development of monoclonal antibodies interacting with cross linked fibrin derivatives has provided an assay of high sensitivity which is not influenced by the presence of fibrinogen or fragments X, Y, D and E. The new assay is relatively simple and more practical than previously described tests which may be applied to plasma, particularly radioimmunoassays requiring antibodies to Dneo and Eneo.12 13 It also represents a distinct advance over our previously reported serum assay using monoclonal antibodies, which could not be used with plasma.7 Fibrinogen interfered in the earlier assay because it was necessary to use a panspecific antibody for capture. In this present modification, the monospecific monoclonal antibody DD-3B6/22 behaved efficiently as a capture antibody, allowing the panspecific monoclonal antibody to be used as the tag material. The sensitivity down to at least 1 ng/ml is also a further advance over the previous method, permitting accurate measurements in all normal plasmas. Both assays can, however, be applied to serum specimens, and unlike assays utilising conventional polyclonal antibodies, they effectively distinguish between the breakdown products of cross linked fibrin and those of fibrinogen (see Fig. 1 ).
The preliminary clinical data provided on patients with proved intravascular coagulation or thrombosis confirm the sensitivity of the procedure and also suggest high specificity. There was no overlap with the normal range in patients with deep venous thrombosis or pulmonary embolism. Conversely, many with deep venous thrombosis gave normal fibrin degradation product assays using a conventional latex procedure. The potential of this assay as a screening test for thrombosis will need to be evaluated by further trials, but, at this point, it would seem to be useful in discriminating between patients with and without thrombosis.
The concentrations found in normal plasma were higher than those measured in serum. These values probably represent the presence of traces of cross linked fibrin derivatives because they can be completely removed from plasma by absorption with the monoclonal antibody DD-3B6/22 bound to Sepharose 4B. The possibility that these cross linked fibrin derivatives are present in vivo as the result of normal fibrinolysis must remain a speculation. The alternative that such low concentrations appearing in anticoagulated plasma from normal subjects may represent an in vitro artefact has to be resolved.
With an approximate correction for dilution of plasma by citrate, assayable fibrin derivatives were invariably lower in serum than in the plasma in the patient groups. There are two possible explanations for this difference. One is that plasma may contain non-clottable fibrin fragments which are occluded in the clot or perhaps bound to fibrin when blood is allowed to clot in vitro. A second mechanism may be that the procedure is able to detect clottable, soluble fibrin complexes which circulate in plasma. In support of this latter possibility we have shown that soluble fibrin complexes formed in vitro by reacting citrated plasma with CaCl2 and low concentrations of thrombin, stopping the reaction with diisopropyl-fluorophosphate before clot formation, in the presence of the protease inhibitor aprotinin have measureable affinity for the monoclonal antibody DD-3B6/22. This antibody also binds to intact cross linked fibrin clots (unpublished observations).
The antibody (DD-3B6/22) has only low affinity for carboxymethylated y-y chains. The implication is that it recognises a conformation resulting from the juxtaposition of two D domains of adjacent fibrin molecules and that it may not necessarily be specific for the presence of y-y cross links. After plasmin degradation, however, DD-3B6/22 will react only with cross linked fibrin fragments and complexes. If these findings are substantiated then DD-3B6/22 assays of serum and plasma performed in tandem will be complementary. The serum level will determine the presence of non-clottable cross linked degradation products, and the excess in plasma may be a measure of circulating soluble fibrin. The combination may offer a new tool for evaluating hypercoagulable states.
The choice of D dimer as the standard reference antigen probably results in lower estimates of cross linked fibrin derivatives than actually exist in plasma and serum, which contain mainly D dimer-E and larger complexes.9 These have lower affinity for the antibody than D dimer (see Fig. 1 ). D dimer is currently favoured as the standard because it is readily purified, although long term stability is doubtful. Preparations of high molecular weight complexes are being studied as possible alternatives to D dimer.
The desirability of a practical assay specific for cross linked fibrin derivatives was first noted by Gaffney,'4 but the end has been difficult to realise. Polyclonal antibodies which are monospecific for cross linked fibrin fragments have been reported.' It would seem, however, that only monoclonal technology will provide antibodies specific for cross
